Palisade Bio (PALI) Peer Comparison

$2.02

$-0.10 (-4.50%)

As on 28-Aug-2026 13:38EDT

Market cap

$366 Mln

Revenue (TTM)

$1 Mln

P/E Ratio

3.1

P/B Ratio

2.9

Div. Yield

0 %

Edit

	Palisade Bio (PALI)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)
Market cap ($ Mln)	366	17,326	16,614	13,400	12,305
Revenue ($ Mln)	1	2,782	1,054	2,436	670
Net Profit ($ Mln)	-31.94	491.50	755.85	860.62	-319.95
Net Margin (%)	-6,388.20	17.67	71.69	35.33	-47.79
RoE (%)	-25.44	110.09	--	42.98	-71.14
Price to Earnings	3.13	36.49	19.38	17.01	--
Price-To-Book	2.95	39.43	10.05	7.27	26.44

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement ($ Mln)

	Palisade Bio (PALI)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)
Operating Revenue	0.50	2,782.29	1,054.37	2,435.92	669.50
Cost of Revenue	0.00	1,982.07	103.47	85.67	19.14
Gross Profit	0.00	760.62	588.53	2,236.43	829.45
Operating Expenses	35.85	216.81	841.45	1,378.74	895.93
Operating Profit (EBIT)	-35.35	583.40	109.45	971.51	-226.44
Other Income	0.00	0.00	0.00	0.00	0.00
Profit before Tax	-31.94	598.92	101.11	1,035.47	-252.08
Provision for Tax	0.00	107.42	-654.74	174.84	20.05
Profit after Tax (Net Income)	-31.94	491.50	755.85	860.62	-319.95
Minority Interest	0.00	0.00	0.00	0.00	-47.83
Consolidated Profit	0.00	0.00	0.00	0.00	0.00

Liabilities ($ Mln)

	Palisade Bio (PALI)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)
Shareholder's Funds	121.75	433.86	1,435.90	1,843.76	465.53
Minority Interest	0.00	0.00	0.00	0.00	-47.83
Non-Current Liabilities	0.32	187.89	384.48	288.55	1,362.63
Current Liabilities	5.25	1,435.43	464.70	361.93	283.35
Total Liabilities	134.34	1,975.47	1,302.02	2,844.42	1,385.30

Assets ($ Mln)

	Palisade Bio (PALI)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)
Non-Current Assets	0.06	1,006.90	895.24	1,243.41	440.60
Current Assets	127.26	1,050.29	1,389.84	1,250.82	1,671.41
Total Assets	134.34	1,975.47	1,302.02	2,844.42	1,385.30
Total Debt*	0.00	120.10	449.89	165.93	864.07
Net Current Assets	0.00	-385.14	0.00	888.90	1,388.07

Cashflow ($ Mln)

	Palisade Bio (PALI)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)
Cash From Operating Activities	-10.85	713.22	51.77	884.27	179.55
Cash Flow from Investing Activities	--	-31.14	-8.15	350.44	-129.29
Cash from Financing Activities	134.44	-860.39	34.89	-969.59	74.01
Net Cash Inflow / Outflow	--	--	--	--	--

Ratios

Profitability Ratios

	Palisade Bio (PALI)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)
ROCE (%)	-24.48	53.56	-30.01	32.82	-0.17
ROE (%)	-25.44	110.09	163.18	42.98	-71.14
ROA (%)	-24.09	15.64	26.53	29.32	-16.12
EBIT Margin (%)	-2,609.00	21.13	5.73	31.04	-0.77
Net Margin (%)	-6,388.20	17.67	71.69	35.33	-47.79
Cash Profit Margin (%)	-6.39	0.00	0.00	0.00	0.00

Growth Ratios

	Palisade Bio (PALI)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)
Revenue Growth (%)	12,400.00	24.67	114.85	9.23	12.22
EBIT Growth (%)	-10.27	18.70	136.39	-3.99	93.17
Net Profit Growth (%)	-169.66	17.50	378.76	42.89	-115.58
EPS Growth (%)	68.60	26.84	353.27	50.42	-73.87
Book Value Growth (%)	5.46	164.02	816.12	-0.70	-13.57

Valuation Ratios

	Palisade Bio (PALI)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)
Price / Earnings	-7.80	36.06	-59.76	15.79	-2,869.63
Price / Book Value	1.01	35.44	-80.42	5.72	10.04
Dividend Yield (%)	--	--	--	--	--
EV/EBITDA	0.15	28.08	-121.54	12.44	25.04
Market Cap ($ Cr)	--	--	--	--	--

Solvency Ratios

	Palisade Bio (PALI)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)
Debt to Equity	0.00	0.00	0.00	0.00	1.77
Short term debt to equity ratio	0.00	0.00	0.05	0.00	0.09
Current Ratio	24.26	0.73	2.99	3.46	5.90
Quick Ratio	24.26	0.73	2.32	3.38	5.90
Interest Coverage	-3,991.63	--	1.62	--	-1.72

Operating Efficiency Ratios

	Palisade Bio (PALI)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)
Debtors to sales (%)	100.00	15.88	21.25	13.74	1.28
Asset Turnover	0.00	0.89	0.37	0.83	0.34
Receivable days	--	50.42	85.52	43.48	1.50
Inventory Days	1,461.00	--	1,056.70	96.17	--
Payable days	120,593.38	6.26	331.01	147.97	221.81
Cash Conversion Cycle	--	--	811.21	-8.32	--

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly